ES2726605T3 - Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón - Google Patents

Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón Download PDF

Info

Publication number
ES2726605T3
ES2726605T3 ES13765886T ES13765886T ES2726605T3 ES 2726605 T3 ES2726605 T3 ES 2726605T3 ES 13765886 T ES13765886 T ES 13765886T ES 13765886 T ES13765886 T ES 13765886T ES 2726605 T3 ES2726605 T3 ES 2726605T3
Authority
ES
Spain
Prior art keywords
compound
ret
kif5b
fusion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13765886T
Other languages
English (en)
Spanish (es)
Inventor
Dana Aftab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of ES2726605T3 publication Critical patent/ES2726605T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • G01N33/5752
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
ES13765886T 2012-09-07 2013-09-09 Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón Active ES2726605T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261698143P 2012-09-07 2012-09-07
PCT/US2013/058768 WO2014039971A1 (en) 2012-09-07 2013-09-09 Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Publications (1)

Publication Number Publication Date
ES2726605T3 true ES2726605T3 (es) 2019-10-08

Family

ID=49226556

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13765886T Active ES2726605T3 (es) 2012-09-07 2013-09-09 Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón

Country Status (6)

Country Link
US (2) US20140121239A1 (enExample)
EP (1) EP2892532B1 (enExample)
JP (2) JP6513567B2 (enExample)
CN (2) CN114129566A (enExample)
ES (1) ES2726605T3 (enExample)
WO (1) WO2014039971A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
TWI511956B (zh) 2009-01-16 2015-12-11 Exelixis Inc 製備n-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之方法
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
PT2621481T (pt) 2010-09-27 2019-11-19 Exelixis Inc Inibidores duplos de met e vegf para o tratamento de cancro da próstata resistente à castração e metástases ósseas osteoblásticas
PL2673262T3 (pl) 2011-02-10 2022-04-11 Exelixis, Inc. Sposoby wytwarzania związków chinolinowych i kompozycje farmaceutyczne zawierające takie związki
ES2639093T3 (es) 2011-09-22 2017-10-25 Exelixis, Inc. Procedimiento para el tratamiento de la osteoporosis
JP6208140B2 (ja) 2011-10-20 2017-10-04 エクセリクシス, インク. キノリン誘導体の調製プロセス
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
EP2892532B1 (en) * 2012-09-07 2019-02-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
CA2907334C (en) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
KR102354963B1 (ko) 2014-02-14 2022-01-21 엑셀리시스, 인코포레이티드 N-{4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐}-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
WO2015161277A1 (en) * 2014-04-18 2015-10-22 Blueprint Medicines Corporation Met fusions
MX375716B (es) * 2014-04-25 2025-03-06 Exelixis Inc Método para tratar adenocarcinoma de pulmón.
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
JP6789923B2 (ja) 2014-07-31 2020-11-25 エグゼリクシス, インコーポレイテッド フッ素18標識化カボザンチニブ及びその類似体の調製方法
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
CN107428760B (zh) 2014-11-16 2021-04-27 阵列生物制药公司 (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
BR112018008357A2 (en) 2015-10-26 2018-11-27 Loxo Oncology, Inc. dot mutations in trk inhibitor resistant cancer and related methods
EA038890B1 (ru) 2015-11-02 2021-11-03 Блюпринт Медсинс Корпорейшн Ингибиторы ret
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
EP3454886A1 (en) 2016-05-13 2019-03-20 Instituto de Medicina Molecular Methods of treating diseases associated with ilc3 cells
HRP20201984T1 (hr) 2016-05-18 2021-04-16 Loxo Oncology, Inc. Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
MY201941A (en) 2017-08-21 2024-03-25 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
MX2020007765A (es) 2018-01-26 2020-09-25 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
WO2019195471A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
CN110862397A (zh) * 2018-08-27 2020-03-06 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
DE102020005002A1 (de) * 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Mittel zur Therapie von Tumorerkrankungen
EP4347645A1 (en) 2021-06-03 2024-04-10 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
CN114354789B (zh) * 2021-12-27 2023-08-29 深圳海王医药科技研究院有限公司 一种同时测定卡博替尼类似物及其有关物质的方法
WO2023230770A1 (en) * 2022-05-30 2023-12-07 Suzhou Singleron Biotechnologies Co., Ltd. Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
MX2011003363A (es) * 2008-10-01 2011-04-27 Ludwig Inst Cancer Res Metodos para el tratamiento de cancer.
TWI511956B (zh) * 2009-01-16 2015-12-11 Exelixis Inc 製備n-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之方法
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
US10023855B2 (en) * 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
WO2013163428A1 (en) * 2012-04-25 2013-10-31 The Regents Of The University Of Colorado Detection of ret fusions in cancer
EP2892532B1 (en) * 2012-09-07 2019-02-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Also Published As

Publication number Publication date
HK1212248A1 (en) 2016-06-10
JP2018203727A (ja) 2018-12-27
JP2015530389A (ja) 2015-10-15
JP6513567B2 (ja) 2019-05-15
EP2892532B1 (en) 2019-02-13
WO2014039971A1 (en) 2014-03-13
US20140121239A1 (en) 2014-05-01
US20150238477A1 (en) 2015-08-27
CN104703600A (zh) 2015-06-10
CN114129566A (zh) 2022-03-04
EP2892532A1 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
ES2726605T3 (es) Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón
ES2874875T3 (es) Procedimiento de tratamiento de adenocarcinoma de pulmón
US9216172B2 (en) Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
US20150057335A1 (en) Novel fusion genes identified in lung cancer
US11155879B2 (en) Method of predicting effects of CDC7 inhibitor
JP7747459B2 (ja) Fgfr阻害薬に対する感受性の判定方法
HK40071406A (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
HK40064013A (en) Method of treating lung adenocarcinoma
HK1212248B (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
JP5119546B2 (ja) 胃を原発巣とする消化管間質腫瘍の悪性化の診断法
NZ725576B2 (en) Method of treating lung adenocarcinoma
HK1235005B (en) Method of treating lung adenocarcinoma
HK40020609A (en) Method of predicting effects of cdc7 inhibitor
HK40020609B (en) Method of predicting effects of cdc7 inhibitor